Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H25N.CH4O3S |
| Molecular Weight | 387.536 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CN(C)CCC=C1C2=CC=CC=C2C(C)(C)C3=CC=CC=C13
InChI
InChIKey=LXKCTBYAJVUILB-UHFFFAOYSA-N
InChI=1S/C21H25N.CH4O3S/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21;1-5(2,3)4/h5-8,10-14H,9,15H2,1-4H3;1H3,(H,2,3,4)
DescriptionCurator's Comment: Description was created based on several sources, including https://www.aci-bd.com/Brand/Adelax.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18331614
Curator's Comment: Description was created based on several sources, including https://www.aci-bd.com/Brand/Adelax.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18331614
Melitracen (HCl) is a tricyclic antidepressant with actions and effects similar to amitriptyline.Melitracen (HCl) is given orally in the treatment of depression. It should be withdrawn gradually to reduce the risk of withdrawl symptoms. Melitracen (HCl) is primarily indicated in conditions like Anxiety, Asthenia, Depression, gastro-intestinal disorders associated with anxiety and agitation. Melitracen is marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol. The way this drug works hasn’t been thoroughly researched, but some hypothesize that it may work similarly to the drugs Imipramine and Amitriptyline. In comparison to older TCAs, this drug is thought to work more quickly with more favorable side effects.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Deanxit Approved UseAnxiety − Depression − Asthenia.
Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression.
Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions.
Dysphoria and depression in alcoholics and drug-addicts. Launch Date1997 |
|||
| Primary | Deanxit Approved UseAnxiety − Depression − Asthenia.
Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression.
Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions.
Dysphoria and depression in alcoholics and drug-addicts. Launch Date1997 |
|||
| Primary | Deanxit Approved UseAnxiety − Depression − Asthenia.
Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression.
Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions.
Dysphoria and depression in alcoholics and drug-addicts. Launch Date1997 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
9.7926 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.6205 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
453.7055 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
477.9061 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
72.793 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
67.1625 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31571834/ |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: FLUPENTIXOL |
MELITRACEN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11% |
MELITRACEN plasma | Homo sapiens |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Comparative study on abdominal acupuncture and western medicine for treatment of menopause depressive disorder]. | 2010-11 |
|
| [Study on catgut implantation therapy compared with Deanxit for treatment of depression]. | 2010-08 |
|
| Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. | 2009-11 |
|
| Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia. | 2008-06-01 |
|
| [Efficacy and safety of Deanxit combined with Wuling Capsule in treating post-stroke depression: a randomized controlled trial]. | 2008-03 |
|
| Purple urine bag syndrome in nursing homes: ten elderly case reports and a literature review. | 2008 |
|
| Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma. | 2007-12-28 |
|
| Validation of a sensitive LC/MS/MS method for simultaneous quantitation of flupentixol and melitracene in human plasma. | 2007-12-21 |
|
| Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method. | 2006-10-16 |
|
| Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. | 2005-12-09 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40185082
Created by
admin on Mon Mar 31 22:00:53 GMT 2025 , Edited by admin on Mon Mar 31 22:00:53 GMT 2025
|
PRIMARY | |||
|
31149-47-0
Created by
admin on Mon Mar 31 22:00:53 GMT 2025 , Edited by admin on Mon Mar 31 22:00:53 GMT 2025
|
PRIMARY | |||
|
53447046
Created by
admin on Mon Mar 31 22:00:53 GMT 2025 , Edited by admin on Mon Mar 31 22:00:53 GMT 2025
|
PRIMARY | |||
|
HS8YY1BM7I
Created by
admin on Mon Mar 31 22:00:53 GMT 2025 , Edited by admin on Mon Mar 31 22:00:53 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
